Barter - Figure 25 - Baysian analysis Text

The Figure summarizes the principal results of DEFINE.[24] Fortunately, this newer CETP inhibitor anacetrapib had no adverse effects on blood pressure, electrolytes, or aldosterone, which clearly differentiates it from torcetrapib. Furthermore, with the primary Bayesian analysis that was used, the result allowed for a conclusion that the event distribution in DEFINE indicated a 94% predictive probability of dismissing a torcetrapib type increase in cardiovascular events. This was not quite 100%, but nothing in biology is 100% and 94% gives sufficient confidence to proceed with further assessment of anacetrapib.

Barter P. J Clin Lipidol. 2011; 5(6).